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Dyslipidemia, a known risk factor for atherosclerosis, is
frequent among both adults and children with chronic
kidney disease. Here, we describe the prevalence and pattern
of dyslipidemia from a cross-sectional analysis of 391 children
aged 1–16 years, enrolled in the multicenter Chronic Kidney
Disease in Children (CKiD) study, with a median glomerular
filtration rate (GFR), measured by the plasma disappearance
of iohexol, of 43ml/min per 1.73m2. Multivariate analysis was
applied to adjust for age, gender, body mass index (BMI),
GFR, and the urinary protein/creatinine ratio. Proteinuria
was in the nephrotic range in 44 and the BMI exceeded the
95th percentile in 57 patients of this cohort. Baseline lipid
analysis found a high prevalence of hypertriglyceridemia in
126, increased non-HDL–C in 62, and reduced HDL–C in 83.
Overall, 177 children had dyslipidemia, of whom 79 had
combined dyslipidemia. Lower GFR was associated with
higher triglycerides, lower HDL–C, and higher non-HDL–C.
Nephrotic-range proteinuria was significantly associated with
dyslipidemia and combined dyslipidemia. Compared with
children with a GFR 450, children with a GFR o30 had
significantly increased odds ratios for any dyslipidemia or for
combined dyslipidemia. Hence, among children with
moderate chronic kidney disease, dyslipidemia is common
and is associated with lower GFR, nephrotic proteinuria, and
non-renal factors including age and obesity.
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Individuals with chronic kidney disease (CKD) suffer an
exceptionally high burden of atherosclerotic cardiovascular
disease (ASCVD).1 Dyslipidemia, a known risk factor for
atherosclerosis, is frequent among both adults and children
with CKD.2,3 In addition, there is evidence to suggest that
dyslipidemia contributes to the initiation and progression
of CKD itself.4–9 Although CKD patients are commonly
burdened with multiple cardiovascular risk factors, dyslipi-
demia is an important focus of clinical CKD research, as it is
both highly prevalent and a potentially modifiable exposure.
Accelerated atherosclerosis in children with CKD is likely.
Within the general population, atherosclerosis begins during
childhood and dyslipidemia is a risk factor for its develop-
ment.10–12 Young adult survivors of childhood end-stage
renal disease (ESRD) experience an extremely high rate of
premature mortality because of ASCVD, their principal cause
of death.13–16 However, compared with the adult population,
data about dyslipidemia in children with CKD remain scarce.
The primary aim of this cross-sectional investigation was
to describe the prevalence and pattern of dyslipidemia in
children with moderate CKD using data collected on
participants in the Chronic Kidney Disease in Children
(CKiD) Study. We also aimed to identify clinical and
laboratory factors associated with dyslipidemia in children
with CKD.
RESULTS
As of May 2009, 574 children had completed a baseline study
visit in CKiD. A subset of 427 children with known age, sex,
race, and CKD diagnosis had complete lipid and glomerular
filtration rate (GFR). After excluding 11 children currently
taking lipid-lowering medication and 25 children known not
to be fasting, 391 children remained for analysis. In 29%
(n¼ 112) of this group, fasting status was not recorded,
whereas the remainder (71%, n¼ 279) of the children were
confirmed to be fasting. Of all GFR measures, 94% (n¼ 368)
were direct (iGFR) by plasma iohexol disappearance.
Characteristics of the study population are shown in Table 1,
including overall lipid measures. In general, the population had
a slight male predominance, was mostly Caucasian, and was
skewed toward overweight. A significant minority (31%) had
moderate or nephrotic-range proteinuria.
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Triglycerides
Figure 1a shows the relationship between triglyceride (TG)
levels and GFR. Univariately, log(TG) and GFR displayed a
linear relationship, with TG levels increasing on average 8%
(95% confidence interval (CI): 5%, 11%) for every 10 ml/min
per 1.73 m2 decrease in GFR (Table 2a). Although a
relationship was suggested between elevated TG and subne-
phrotic proteinuria, this was clearer in subjects with
nephrotic-range proteinuria, who displayed TG levels on
average 55% higher (95% CI: 32, 84) than those with normal
protein: creatinine ratio (Up/c). The prevalence of hyper-
triglyceridemia in children with nephrotic-range proteinuria
was 61%, as compared with 21, 30, and 24% in children with
normal, mild, and moderate proteinuria, respectively.
After multivariate adjustment, higher TG levels continued
to be associated with increased age, decreased GFR,
proteinuria, and being either overweight or obese
(Table 2a). Children who were overweight or obese, or had
nephrotic proteinuria, had TG levels on average 30% higher
than those of children with normal weight and normal Up/c,
a magnitude of association greater than that for a 30 ml/min
per 1.73 m2 decrease in GFR (23%, not shown in table).
Higher TG levels were associated with mild proteinuria
(18% increase in TG) and nephrotic proteinuria (34%
increase in TG), but not with moderate proteinuria
(3% increase in TG). Restricting analysis to the 279 children
who self-reported overnight fasting did not qualitatively
change the reported associations.
Table 1 | Study population characteristics (N=391)
Characteristic Median [IQR] or % (n)
Age (years) 12 [8,15]
Male 60% (236)
Race
White 71% (277)
Black 15% (57)
Other/mixed 15% (57)
Hispanic ethnicitya 14% (55)
GFR (ml/min per 1.73m2)b 43 [32,55]
Glomerular CKD 19% (76)
Proteinuria (Up/c; mg/mg)a 0.4 [0.2,1.2]
Normal (Up/co0.2) 27% (103)
Mild (0.2pUp/co1.0) 42% (160)
Moderate (1.0pUp/co2.0) 19% (72)
Nephrotic (Up/cX2.0) 12% (44)
BMI percentilea,c 61 [32,85]
Overweight (85oBMI percentilep95)c 10% (37)
Obese (BMI percentile495)c 15% (57)
Triglycerides (mg/dl) 106 [75,141]
Total cholesterol (mg/dl) 174 [154,194]
HDL cholesterol (mg/dl) 47 [40,55]
non-HDL cholesterol (mg/dl) 126 [107,147]
Abbreviations: BMI, body mass index; CDC, Centers for Disease Control and
Prevention; CKD, chronic kidney disease; GFR, glomerular filtration rate; HDL,
high-density lipoprotein; IQR, interquartile range; Up/c, protein: creatinine ratio.
aMissing data: Hispanic ethnicity, n=3; Up/c, n=12; BMI percentile, n=16.
bn=368 (94%) directly measured by iohexol plasma disappearance; n=23 (6%) based
on estimating equation.
cAge- and gender-specific BMI percentiles were calculated using 2000 CDC standard
growth charts for United States children.57
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Figure 1 |Relation of lipid measurements to GFR. (a) Triglycerides. (b) HDL–C. (c) Non-HDL–C. GFR, glomerular filtration rate; HDL–C,
high-density lipoprotein cholesterol.
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Cholesterol
The cohort demonstrated modest hypercholesterolemia: 21%
of the cohort had total cholesterol (TC) 4200 mg/dl;
21% had high-density lipoprotein cholesterol (HDL–C)
o40 mg/dl, and 16% had non-HDL–C 4160 mg/dl.
HDL–C Analysis
As shown in Figure 1b, a linear relationship was observed
between log(HDL–C) and GFR. After multivariate adjust-
ment, lower HDL–C levels were associated with increased age,
decreased GFR, mild proteinuria, and obesity (Table 2b). In
general, the magnitudes of association were smaller between
HDL–C and the set of modeled risk factors than those
observed with TG. Each 10 ml/min per 1.73 m2 decrease of
GFR was associated with a 3% decrease in HDL–C (95% CI:
4%, 1%). Compared with those children without
proteinuria, HDL–C levels were 7% lower (95% CI 13%,
2%) in children with mild proteinuria, whereas children
with moderate or nephrotic-range proteinuria showed no
decrease in HDL–C levels. Obese children had average
HDL–C levels 14% (95% CI: 20%, 8%) lower than those
neither overweight nor obese.
Non-HDL–C and TC analysis
There was a borderline statistically significant and quantita-
tively small association between higher non-HDL–C and
lower GFR (Figure 1c). After multivariate adjustment, for
each 10 ml/min per 1.73 m2 lower GFR, non-HDL–C was
Table 2a | Results of uni- and multivariate linear regression models of log-transformed serum total triglycerides (TG) on select
clinical CKD and anthropometric measures (N=391)
% Change in TGa
Unadjusted Adjustedb
Estimated (95% CI) P-value Estimated (95% CI) P-value
Age (per 3-year increase) 5% (2, 9) o0.01 4% (0, 7) 0.03
Male 0% (9, 11) 0.98 1% (8, 11) 0.84
GFR (per 10ml/min per 1.73m2 decrease) 8% (5, 11) o0.01 7% (4, 10) o0.01
Proteinuria (versus normal, Up/co0.2)
Mild (0.2pUp/co1.0) 21% (7, 36) o0.01 18% (5, 33) o0.01
Moderate (1.0pUp/co2.0) 15% (0, 32) 0.06 3% (11, 19) 0.69
Nephrotic (Up/cX2.0) 55% (32, 84) o0.01 34% (13, 59) o0.01
BMI percentile (versus BMI percentilep85)
Overweight (85oBMI percentilep95) 18% (0, 40) 0.04 29% (10, 51) o0.01
Obese (BMI percentile495) 28% (12, 47) o0.01 30% (13, 48) o0.01
Abbreviations: BMI, body mass index; CI, confidence interval; CKD, chronic kidney disease; GFR, glomerular filtration rate; Up/c, protein: creatinine ratio.
aPercent change of lipid level¼ (ebjDxj1) 100 where xj and bj for j=1,2,3,y.,k are the k independent variables and regression coefficients, respectively.
bAdjusted for all variables shown. Based on N=364 owing to missing data (n=12 missing Up/c; n=16 missing BMI percentile).
Table 2b | Results of uni- and multivariate linear regression models of log-transformed HDL–C on select clinical CKD and
anthropometric measures (N=391)
% Change in HDL–Ca
Unadjusted Adjustedb
Estimated (95% CI) P-value Estimated (95% CI) P-value
Age (per 3-year increase) 5% (6, 3) o0.01 5% (7, 3) o0.01
Male 3% (7, 2) 0.28 5% (9, 0) 0.06
GFR (per 10ml/min per 1.73m2 decrease) 2% (4, 1) o0.01 3% (4, 1) o0.01
Proteinuria (versus normal, Up/co0.2)
Mild (0.2pUp/co1.0) 7% (13, 1) 0.02 7% (13, 2) 0.01
Moderate (1.0pUp/co2.0) 1% (8, 7) 0.88 4% (3, 12) 0.31
Nephrotic (Up/cX2.0) 5% (13, 4) 0.29 3% (6, 12) 0.51
BMI percentile (versus BMI percentilep85)
Overweight (85oBMI percentilep95) 3% (11, 6) 0.51 7% (14, 1) 0.09
Obese (BMI percentile495) 13% (19, 6) o0.01 14% (20, 8) o0.01
Abbreviations: BMI, body mass index; CI, confidence interval; CKD, chronic kidney disease; GFR, glomerular filtration rate; HDL–C, high-density lipoprotein cholesterol; Up/c,
protein: creatinine ratio.
aPercent change of lipid level¼ (ebjDxj1) 100 where xj and bj for j=1,2,3,y.,k are the k independent variables and regression coefficients, respectively.
bAdjusted for all variables shown. Based on N=364 owing to missing data (n=12 missing Up/c; n=16 missing BMI percentile).
1156 Kidney International (2010) 78, 1154–1163
or ig ina l a r t i c l e JM Saland et al.: Dyslipidemia in children with CKD
B2% greater (95% CI: 0%, 3%), as shown in (Table 2c). No
relationship was observed between TC and GFR (data not
shown). In contrast, compared with normal Up/c, nephrotic-
range proteinuria was associated with a 31% (95% CI: 18,
44%) increase in non-HDL–C and a 23% (95% CI: 14, 32%)
increase in TC (data not shown).
Dyslipidemic profiles
One-third (32%) of children had elevated TG, whereas 21%
had low HDL–C and 16% had high non-HDL–C. Of the 45%
with dyslipidemia, 45% displayed combined (multiple
marker) dyslipidemia, defined as the presence of two or
more lipid abnormalities, as shown in Table 3.17,18 Although
both low HDL–C and high non-HDL–C were univariately
associated with hypertriglyceridemia (w2 P-valueo0.01 for
both), the joint bivariate distribution of the two abnormal
cholesterol markers did not differ by hypertriglyceridemia
status (P¼ 0.16 by Breslow–Day test for homogeneity of odds
ratios), suggesting that neither abnormal cholesterol marker
was more likely to be associated with hypertriglyceridemia
than the other.
Analysis of the prevalence of dyslipidemia profiles is
presented in Figure 2a and b and Table 4. As shown in
Figure 2a, lower levels of GFR were associated not only with
an increased prevalence of dyslipidemia, as defined by the
presence of at least one abnormal lipid measure, but also with
an increased prevalence of combined dyslipidemia (multiple
abnormal lipid measures; Po0.01 for differences in the
distribution of number of dyslipidemia markers by GFR
category based on w2-test of association for an RC
contingency table). Similarly, increased prevalence of dysli-
pidemia and combined dyslipidemia was also seen with
increasing levels of proteinuria (Figure 2b; Po0.01 for
differences in the distribution of number of dyslipidemia
markers by level of proteinuria based on w2-test of association
for an RC contingency table).
The results of the multivariate partial proportional odds
models (PPOM) estimating associations between the pre-
valence of dyslipidemic measures and GFR, proteinuria, age,
sex, and body mass index (BMI) are displayed in Table 4.
The adjusted relative odds of having combined dyslipidemia
(X2 versus o2 lipid abnormalities) for different levels of
Table 2c | Results of uni- and multivariate linear regression models of log-transformed non-HDL–C on select clinical CKD and
anthropometric measures (N=391)
% Change in non-HDL–Ca
Unadjusted Adjustedb
Estimated (95% CI) P-value Estimated (95% CI) P-value
Age (per 3-year increase) 1% (1, 3) 0.19 0% (2, 2) 0.84
Male 0% (5, 6) 0.96 1% (6, 5) 0.81
GFR (per 10ml/min per 1.73m2 decrease) 2% (1, 4) o0.01 2% (0, 3) 0.05
Proteinuria (versus normal, Up/co0.2)
Mild (0.2pUp/co1.0) 7% (0, 14) 0.05 6% (1, 14) 0.07
Moderate (1.0pUp/co2.0) 4% (4, 12) 0.43 2% (7, 10) 0.72
Nephrotic (Up/cX2.0) 32% (21, 45) o0.01 31% (18, 44) o0.01
BMI percentile (versus BMI percentilep85)
Overweight, 85oBMI percentilep95 4% (5, 14) 0.40 7% (3, 17) 0.16
Obese, BMI percentile495 13% (5, 22) o0.01 12% (4, 21) o0.01
Abbreviations: BMI, body mass index; CI, confidence interval; CKD, chronic kidney disease; GFR, glomerular filtration rate; HDL–C, high-density lipoprotein cholesterol; Up/c,
protein: creatinine ratio.
aPercent change of lipid level¼ (ebjDxj1) 100 where xj and bj for j=1,2,3,y.,k are the k independent variables and regression coefficients, respectively.
bAdjusted for all variables shown. Based on N=364 owing to missing data (n=12 missing Up/c; n=16 missing BMI percentile).
Table 3 | Prevalence of dyslipidemia markers (N=391)
Number of markers of
dyslipidemia
TG
4130mg/dl
HDL–C
o40mg/dl
non-HDL–C
4160mg/dl % (n) % (n)
0/3 No No No 55% (214) 55% (214)
Yes No No 12% (47)
1/3 No Yes No 8% (31) 25% (98)
No No Yes 5% (20)
2/3 Yes Yes No 9% (37)
Yes No Yes 7% (27) 16% (64)
No Yes Yes 0% (0)
3/3 Yes Yes Yes 4% (15) 4% (15)
Totals by marker 32% (126) 21% (83) 16% (62)
Abbreviations: HDL–C, high-density lipoprotein cholesterol; TG, triglyceride.
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proteinuria, increasing age, and female sex were similar to
those for having any level of dyslipidemia (X1 versus 0 lipid
abnormalities), and were therefore modeled using a single
estimate (that is, proportional odds was met). Compared
with normal proteinuria, nephrotic proteinuria was strongly
associated with (a) dyslipidemia in general, and to an equal
degree with (b) combined dyslipidemia (OR¼ 4.16, 95%
CI: 1.96, 8.79, for both estimates). Mild proteinuria and
increasing age demonstrated similar relationships with
dyslipidemia, although to a lesser degree than nephrotic-
range proteinuria.
Lower GFR was associated with dyslipidemia. However,
unlike with proteinuria, GFR displayed nonproportional
odds with respect to overall and combined dyslipidemia
(Table 4): lower GFR was more strongly associated with
combined dyslipidemia than with overall dyslipidemia.
Although children with GFRo30 were about three times
more likely to have any dyslipidemia than children with
GFRX50 ml/min per 1.73 m2, they were eight- to nine times
more likely to have combined dyslipidemia than children
with GFRX50 ml/min per 1.73 m2. Similarly, although
children with GFR 30–40 ml/min per 1.73 m2 did not have
statistically significant higher odds of dyslipidemia compared
with children with GFRX50 ml/min per 1.73 m2, they did
have higher odds of having combined dyslipidemia
(OR¼ 3.21, 95% CI 1.47, 7.01). Being overweight or obese
also displayed nonproportional odds with respect to
dyslipidemia outcomes. Although overweight or obese indi-
viduals were two- to three times more likely to have any
dyslipidemia than normal weight children, they were five- to
seven times more likely to have combined dyslipidemia.
DISCUSSION
This cross-sectional analysis of baseline lipid data from the
CKiD cohort demonstrates that among children with
moderate CKD, dyslipidemia is common and independently
associated with lower GFR and nephrotic-range proteinuria.
In particular, we report a high prevalence of hypertrigly-
ceridemia, increased non-HDL–C, reduced HDL–C, and
combined dyslipidemias, particularly with lower GFR.
Nephrotic-range proteinuria is associated with increased
TG and non-HDL–C, without significant effect on HDL–C.
Although these findings are compatible with data from adult
populations with CKD,19 this report is a significant con-
tribution beyond the adult literature, because the majority of
participants have primary renal disease and few coexisting
conditions; hence, the dyslipidemic effects of CKD are more
clearly delineated. The clinical significance of the high
prevalence of ‘atherogenic dyslipidemia’20–22 in this pediatric
population lies in the potential risks of premature morbidity
and mortality due to accelerated ASCVD, as well as the
potential to accelerate CKD progression.
The primary mechanisms of dyslipidemia in CKD are
thought to involve impaired TG lipolysis, associated with
increased apolipoprotein C-III (an inhibitor of lipoprotein
lipase) and reduced insulin sensitivity in the vascular
endothelium of skeletal muscle and other major sites of TG
(fatty acid) energy utilization.3 As a result, chylomicron and
very-low-density lipoprotein (VLDL) remnants (in our study,
these are best represented by non-HDL–C) are increased, and
there is secondary TG enrichment of all of the lipoprotein
fractions. TG enrichment of HDL mediated by cholesterol
ester transfer protein is of particular relevance, as it
simultaneously depletes cholesterol from HDL. Furthermore,
TG enrichment of HDL leads to its accelerated degradation,
noting that impaired maturation of HDL may also contribute
to lower HDL–C. Conversely, impaired hepatic clearance of
non-HDL lipoproteins results in prolonged circulation, and
therefore higher serum concentrations. Our findings are
consistent with these proposed mechanisms, both in terms of
individual lipid abnormalities and combined dyslipidemia.
It is noteworthy that although combined dyslipidemias
were present in only 20% in our overall study population,
among those children with dyslipidemia, almost half had
combined dyslipidemia. Even after adjusting for age, sex,
proteinuria level, and BMI, lower kidney function was
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strongly associated with combined dyslipidemia. The excess
burden of combined dyslipidemia was present among
children with GFR in the 30–40 ml/min per 1.73 m2 range,
but more evident among children with GFRo30 ml/min per
1.73 m2: they were three times more likely to have some
profile of dyslipidemia (65% prevalence) and nearly nine
times more likely (39% prevalence) to have combined
dyslipidemia. This suggests that declining GFR progressively
elicits and intensifies abnormal lipoprotein metabolism, both
in terms of the proportion expressing dyslipidemia and the
degree to which it is expressed. It is important to highlight
that the presented odds of dyslipidemia and combined
dyslipidemia are not in relation to healthy children, but
rather to other children in the cohort with CKD and
GFR450 ml/min per 1.73 m2. Therefore, as striking as the
relative odds of dyslipidemia are, these findings likely under
represent the odds of dyslipidemia in relation to the general
population.
Little information exists about the dyslipidemic effects of
proteinuria in the subnephrotic range and our results are
somewhat unexpected. Compared with no proteinuria, mild
proteinuria (0.2pUp/co1.0) was associated with higher TG,
but the next higher level of proteinuria (1.0pUp/co2.0) was
not. Lower HDL–C was associated with mild proteinuria
despite the fact that HDL–C was not affected by nephrotic-
range proteinuria. We interpret these findings with caution,
considering these are subgroup analyses and there is potential
for unknown confounders despite multivariate adjustment.
At the same time, analysis of proteinuria as a categorical
variable is useful, as this approach provides results that are
both clinically applicable and that quantitatively acknowledge
significant elements of nonlinearity that exist between lipid
levels and continuous Up/c values (data not shown).
It is worthwhile to consider potential mechanisms to
explain the dyslipidemic effects of the various levels of
proteinuria. The lipid profile of nephrotic syndrome reflects a
composite and extreme expression of multiple concomitant
disturbances of lipoprotein metabolism,23 and we can
hypothesize that intermediate levels of proteinuria elicit
graded and differential expression of those pathophysiologi-
cal mechanisms. For example, lipolysis may be inhibited with
only mild proteinuria, leading to increased TG and resulting
in decreased HDL–C, via (cholesterol ester transfer protein-
mediated) exchange of cholesteryl esters into apolipoprotein
B lipoproteins in exchange for TG. Decreased lecithin–
cholesterol acyltransferase activity could also reduce HDL–C.
Hepatic expression of the scavenger receptor class B member
1 (also known as SR-B1, a receptor for HDL that mediates
the selective uptake of HDL–C) might be diminished by
increasing degrees of proteinuria, reducing reverse cholesterol
transport, and restoring HDL–C levels. The latter might
sustain cholesteryl esters–TG exchange, facilitating TG
catabolism via the action of hepatic lipase on TG-enriched
HDL, offering a potential explanation of the null effect of
moderate proteinuria on TG. With nephrotic-range protei-
nuria, perhaps the hepatic lipase pathway is downregulated
or becomes fully saturated, allowing unmitigated elevation of
TG despite preserved HDL–C.
A general limitation of defining dyslipidemia in children is
a lack of a comprehensive normative set of data that includes
TG levels in young (o12 years) children and significant
variability in lipid values with respect to gender, age, and
Table 4 | Adjusted odds ratios (95% CI) for the prevalence of dyslipidemia markersa using partial proportional odds model for
ordinal response variables (N=364)
Adjusted OR (95% CI)b
Variable 1+ markers versus 0 markers 2+ markers versus o2 markers P-value for difference in ORs
GFR (ml/min per 1.73m2)
X50 1.00 (ref) 1.00 (ref) —
(40–50) 0.66 (0.34, 1.28) 2.16 (0.87, 5.36) 0.002
(30–40) 1.65 (0.92, 2.97) 3.21 (1.47, 7.01) 0.091
o30 2.90 (1.47, 5.70) 8.58 (3.70, 19.88) 0.007
Proteinuria (Up/c)
Normal (Up/co0.2) 1.00 (ref) 1.00 (ref) —
Mild (0.2pUp/co1.0) 1.95 (1.14, 3.33) 1.95 (1.14, 3.33) NAc
Moderate (1.0pUp/co2.0) 1.33 (0.68, 2.58) 1.33 (0.68, 2.58) NAc
Nephrotic (Up/cX2.0) 4.16 (1.96, 8.79) 4.16 (1.96, 8.79) NAc
Age (per 3-year increase) 1.27 (1.07, 1.50) 1.27 (1.07, 1.50) NAc
Male versus female 1.18 (0.76, 1.85) 1.18 (0.76, 1.85) NAc
BMI percentile
Normal (BMI percentilep85) 1.00 (ref) 1.00 (ref) —
Overweight (BMI percentile (85–95)) 2.82 (1.31, 6.03) 6.75 (2.78, 16.35) 0.022
Obese (BMI percentile 495) 2.43 (1.33, 4.45) 5.38 (2.64, 10.97) 0.022
Abbreviations: BMI, body mass index; CI, confidence interval; GFR, glomerular filtration rate; HDL–C, high-density lipoprotein cholesterol; NA, not applicable; TG, triglyceride;
Up/c, protein: creatinine ratio.
aMarkers of dyslipidemia are: TG4130mg/dl, HDL–Co40mg/dl, and non-HDL–C4160mg/dl.
bAll models contain the variables shown in the table.
cModeled with a single estimate (proportional odds).
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ethnicity. Furthermore, because ASCVD does not occur in
the general population of children, levels associated with
‘risk’ must be inferred from adult populations. We adopted
conservative cut points to define ‘dyslipidemia’ with respect
to these considerations; as such, our results may further
underestimate the prevalence of dyslipidemia, particularly in
younger children and among African-American children in
the cohort, in whom TG levels are generally lower. Our
analysis, however, did not rely only on these cut points; the
variation of lipids with GFR and proteinuria was indepen-
dent of such considerations. Another limitation of this report
is the lack of comprehensive lipoprotein analysis. Alterations
in lipoprotein particle number, differences in apolipoprotein
content, and biophysical abnormalities of lipoproteins such
as small dense low-density lipoproteins or altered oxidation
status are relevant examples of expected abnormalities in
CKD. As discussed below, the performance of the direct
HDL–C assay could hypothetically be affected by those
unique abnormalities, noting that the other techniques
suitable for automation and small sample volumes are also
subject to this problem. For example, a mean difference of
3.5 mg/dl HDL–C between an unrelated homogenous assay
and a precipitation technique was reported in nephrotic
subjects.24 Stored biorepository samples, samples obtained at
future visits, and analysis of important ancillary measures,
such as insulin, will provide opportunity for further
investigation of these important physiological and technical
issues. Finally, the cross-sectional design of the analysis does
not permit us to draw conclusions about the temporal
relationship between dyslipidemia and CKD progression. The
longitudinal design of CKiD is ideal for addressing this
limitation, and ongoing study goals include describing the
evolution of dyslipidemic profiles over time and in relation to
CKD progression.
The CKiD study has many other strengths, including a
large sample size, precise measurement of GFR by iohexol
clearance, and standardized demographic, clinical, and
laboratory measures. These aspects of the study, in addition
to the previously mentioned advantage of studying lipopro-
tein physiology in children with primary CKD and little
comorbidity, greatly enhance the significance of the findings.
Discussion of the risk of atherosclerosis in the CKiD
cohort requires a long-term perspective about the lifetime of
children with CKD. Unfortunately, CKD remains an
irreversible and progressive condition. Historically, the
majority of children with significant CKD develop ESRD—
half within 5 years, 70% within 10 years.25,26 Functional
abnormalities of the vascular endothelium have implicated
ASCVD in children with moderate (stage 3–4) CKD and
ESRD.27–36 Subclinical ASCVD during childhood has been
demonstrated by vascular imaging, in small autopsy series,
and by sampling vasculature at the time of kidney transplant
during the course of childhood CKD/ESRD.35–42 The
expected remaining lifetime after ESRD in the 0- to 14-year
age group is 30 years,43 and the principal cause of death
during young adulthood is premature cardiovascular disease,
including ASCVD.13–16 Dyslipidemia and other CVD risk
factors are a research focus, because they are deep-rooted
barriers to improving long-term survival in this population.
This study does not address treatment of dyslipidemia
among children with CKD. Surprisingly, although the
dyslipidemic profile itself is amenable to pharmaceutical
treatment in CKD and ESRD, this has not been convincingly
demonstrated to reduce mortality. Recently, two large clinical
trials (‘SHARP’ and ‘AURORA’) were initiated to answer the
question of whether low-density lipoprotein-lowering ther-
apy benefits patients with CKD or ESRD.44,45 Recently, the
results of AURORA indicated that rosuvastatin has no effect
on ASCVD-related mortality in hemodialysis patients.
SHARP is still ongoing. Two other studies addressing the
issue of whether statin therapy slows progression of CKD issue
are underway.46,47 These studies should help fill the gap in
evidence-based treatment recommendations for adult CKD
patients and even greater uncertainty about potential use of
pharmaceutical agents to treat dyslipidemia among children.
Current guidelines for the management of dyslipidemias
in patients with severe CKD from the 2003 National Kidney
Foundation/Kidney Disease Outcomes Quality Initiative2 do
encompass children from the onset of puberty. Given the
high prevalence of dyslipidemia in the CKiD cohort, our
findings support the recommendation to screen children with
CKD for dyslipidemia.
METHODS
The CKiD study is a multicenter prospective observational cohort
study of CKD in children. The design and methods have been
previously published; the study protocol was approved by the
institutional review board of each participating center.48 Briefly,
children with moderate CKD (estimated creatinine clearance
30–90 ml/min per 1.73 m2, as calculated by the original Schwartz
equation49,50) and between the ages of 1 and 16 years were eligible to
enter the study following signed written consent. Exclusion criteria
included previous malignancy, transplantation, dialysis within
3 months, and a limited number of other conditions.
Data were collected through the second study visit, when serum
TGs, TC, and HDL–C were first measured in CKiD participants.
Samples were drawn after an overnight fast of at least 10 h. Free
access to water was allowed.
Blood was drawn into a serum separator tube and allowed to clot
at room temperature for 30 min before centrifugation and serum
separation. Serum was shipped to the central CKiD laboratory by
next day mail or (if the next day was not a working laboratory day)
refrigerated at 4 1C and shipped the next available day. All lipid
measurements were automated (Siemens Advia 2400 analyzer,
Siemens, Deerfield, IL, USA). Serum TG and TC measurement
followed routine enzymatic methods; HDL–C was analyzed by the
Bayer (Siemens Diagnostics, Deerfield, IL, USA) clinical method for
ADVIA 2400 direct HDL–C (D-HDL) V 1.00.00 technique. Briefly,
this involves detection of HDL–C following selective elimination of
cholesterol from chylomicron and very-low-density lipoprotein
remnants from the detection reactions.51 As older techniques have
slightly different performances in subjects with CKD, it should be
noted that CKD-specific validation of this method is lacking. However,
this homogenous HDL–C technique is not subject to interference by
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TG o1700 mg/dl or anemia, and is commercially certified via
comparison protocols against multiple other HDL–C techniques. In
all uses, analyzer calibration was confirmed by known standards. Non-
HDL–C was calculated as the difference between TC and HDL–C.
The following cut points were used to define the presence of
dyslipidemia: TG4130 mg/dl, HDL–Co40 mg/dl, and non-
HDL–C4160 mg/dl. These cut points were based on: (a) normative
NHANES data available for children aged 12 years and older, (b)
normative data of the Lipid Research Clinic data set, and (c) levels
frequently considered atherogenic in adults.22,52,53
For the majority of study participants, direct measurement of
GFR was accomplished by the plasma disappearance of iohexol
(Ominipaque, GE Healthcare, Princeton, NJ, USA) method (iGFR),
as detailed previously.54 In the event iGFR was not available, GFR
was estimated using a published estimating equation developed
within this study population.55 In this paper, the pooled grouping of
iGFR and estimated GFR is referred to as GFR. Total urine protein
and urine creatinine were measured in a first morning urine sample
and expressed as the Up/c in units of mg/mg. Details of the
techniques used to measure Up/c in CKiD have been published.56
Proteinuria was categorized as normal (Up/co0.2), mild (0.2pUp/
co1.0), moderate (1.0pUp/co2.0), or nephrotic (Up/cX2.0).
Nonlaboratory data were obtained concomitantly using standar-
dized forms and physical exam. Data collected and used in the
current analysis include age, sex, race, ethnicity, height, weight,
and primary CKD diagnosis. BMI was calculated as weight/height2
(kg/m2). Age- and gender-specific BMI percentiles were calculated
using 2000 Centers for Disease Control and Prevention standard
growth charts for United States children.57 Overweight was defined
as a BMI between the 85 and 95th percentiles, obesity as a BMI
495th percentile. CKD diagnosis was classified as glomerular or
nonglomerular; a more detailed description of this classification for
specific diagnoses is published.56
Analysis was restricted to individuals with known age, sex, race,
GFR, and CKD diagnosis, as well as complete lipid measures.
Excluded from the analysis were children receiving lipid-lowering
medication and those who were known to have been nonfasting at
the time the blood sample was obtained.
Statistical analysis
Clinical and demographic characteristics for the study population
were summarized using medians and interquartile ranges for
continuous variables and frequencies and percentages for categorical
variables. Of primary interest was a comprehensive description of
the relationship between the lipid concentrations and the major
markers of CKD, namely, GFR and proteinuria. Other variables of
interest as well as potential confounders (selected a priori of
analysis) included overweight status, age, and sex.
Scatter plots of the log-transformed lipid measures on log-
transformed GFR were developed and overlayed with lowess
smoothing curves. Univariate and multivariate linear regression
models were used to quantify the association between the respective
log-transformed lipid levels and the risk factors of interest. These
models took the form:
log lipid levelð Þ ¼ aþ
Xk
j¼1
bjxj þ e
where a is the intercept, xj and bj for j¼ 1,2,3,y.,k are the k
independent variables and regression coefficients, respectively, and e
is the error assumed to be normally distributed with mean zero and
variance s2.58 Each of the regression coefficients, bj, estimates
average changes in the log-transformed value of the lipid marker for
a unit change in the respective independent variable, xj. As such, the
antilog of bjDxj can be interpreted as a proportional lipid level (that
is, percent change) associated with a change in the independent
variable, Dxj. That is,
Percent change of lipid level ¼ ebjDxj  1 100
Specifically, for categorical independent variables, we used
Dxj¼ 1 representing the effect of being in a given category relative
to the reference category; to describe the effect of continuous
independent variables, we used Dxj¼ 3 years for age and Dxj¼10
for GFR (that is, a decrease of 10 ml/min per 1.73 m2).
The lipid markers were analyzed as log-transformed values to meet
the assumption that the residuals of the regression models would be
normally distributed. The validity of this assumption was confirmed
by fitting a generalized gamma distribution and assessing whether the
shape parameter estimate was statistically different from zero.59
A second goal was to describe the prevalence and coprevalence of
the three separate markers of dyslipidemia in children with CKD.
Prevalence of dyslipidemia by individual marker (high TG, low
HDL, and high non-HDL) was summarized to show how the three
markers jointly distribute themselves. Statistical independence of the
three markers was assessed using Pearson’s w2-tests for independence
and the Breslow–Day test for homogeneity of odds ratios.
A third goal was to describe the association of the number of
dyslipidemia markers presented by a child with the aforementioned
CKD risk factors of interest. In this analysis, a subject’s GFR was
classified asX50, (50–40), (40–30), oro30 ml/min per 1.73 m2. The
w2-Tests of association were performed on 4 4 contingency tables
to test for differences in the distribution of number of dyslipidemia
markers (0, 1, 2, or 3) in subjects across (a) the four categories of
GFR, and (b) the four categories of proteinuria. Because a relatively
small number of children had three markers of dyslipidemia,
subjects were classified as having zero, one, or two, or more
dyslipidemia markers for subsequent analysis. Using the SAS
GENMOD procedure, multivariate PPOM60,61 were fit to this
ordinal categorical variable with the same set of independent (risk
factor) variables as the lipid-specific linear regression models
described above. As an extension of the more commonly used
proportional odds model (cumulative logit), the PPOM allows for
nonproportional odds, as the binary cutoff of the ordinal outcome
variable is moved from X1 versus 0 markers to X2 versus o2
markers. In other words, for a given risk factor (for example,
GFRo30 versus GFRX50), the relative odds of having combined
dyslipidemia (X2 markers) may be substantially stronger than the
relative odds associated with having any dyslipidemia (X1 markers).
The PPOM allows for such nonlinearity where it is warranted, thus
allowing for a better fit of the data.
All analyses were performed using SAS 9.1 (SAS Institute, Cary,
NC, USA); accompanying figures were created using S-Plus 8.0
(Insightful, Seattle, WA, USA). Significance tests with a P-value
o0.05 were considered statistically significant.
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